Accord BioPharma and Intas Pharmaceuticals Aim for Growth with UDENYCA® Acquisition

Accord BioPharma and Intas Pharmaceuticals Pursue Growth through UDENYCA® Acquisition

Accord BioPharma, the American specialty division of Intas Pharmaceuticals, recently announced a significant development in its growth strategy. The company has entered into an agreement to acquire the UDENYCA® (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc. This acquisition not only expands Accord's product portfolio but also strengthens its position in the competitive biosimilar market across the United States.

What is UDENYCA®?

UDENYCA® is a biosimilar to Neulasta®, primarily utilized to prevent infections in patients undergoing chemotherapy, a common risk associated with the treatment of non-myeloid malignancies. Since its launch in 2019, UDENYCA® has seen impressive sales figures, totaling $127.1 million in the fiscal year 2023. The product is distinctive for offering various administration options: prefilled syringes, an autoinjector, and an on-body injector, tailoring to the preferences and needs of patients and healthcare providers alike.

Strategic Acquisition for Market Expansion

Chrys Kokino, the U.S. President of Accord BioPharma, expressed enthusiasm about the acquisition, citing it as an important step towards enhancing their operational footprint in the U.S. biosimilar market. By integrating UDENYCA® into their existing portfolio, Accord aims to meet the growing demand for affordable and effective treatments, thus improving accessibility and patient care.

In a statement, Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals, highlighted two appealing reasons for pursuing the acquisition: the notable sales history of UDENYCA® and its flexibility in administration approaches. The on-body injector, in particular, promises to make treatment more accessible for patients, especially those residing far from treatment facilities.

Benefits for Patients and Healthcare Providers

With UDENYCA® now a part of Accord’s offerings, the company is poised to provide enhanced options for managed care and patient support. Over 300,000 patients have been treated with UDENYCA® since its introduction, underscoring its impact on improving patient outcomes. The flexibility and user-friendliness of UDENYCA® make it an invaluable component of treatment regimens designed to combat infections following chemotherapy.

The anticipated closing of this acquisition is set for the first quarter of 2025. In this transition, Accord BioPharma plans to incorporate the experienced workforce from Coherus, aiming to strengthen its operational capabilities around UDENYCA®.

Looking Ahead: Future Prospects in Biosimilars

As the biosimilar sector continues to expand, the acquisition of UDENYCA® represents a strategic move for Accord BioPharma and Intas Pharmaceuticals. Their commitment to patient-centric business practices not only reflects a dedication to providing cost-effective therapies but also aligns with the pressing need for innovation within the healthcare landscape.

Accord BioPharma is driven by its mission to enhance the patient experience by offering therapies that are affordable and accessible, which in turn enables more patients to receive essential treatments. With a deepening portfolio of biosimilars, the company is prepared to play a critical role in the continued evolution of oncology, immunology, and critical care treatments in the U.S. market.

Conclusion

The acquisition of UDENYCA® by Accord BioPharma marks a significant advancement in the company’s strategy to enhance its product offerings and market share. As they prepare for the transition, both Accord and Intas Pharmaceuticals look forward to delivering more accessible, innovative treatment options to patients across the nation, solidifying their leadership in the rapidly growing biosimilar sector.